https://www.nxtpsychedelics.com/news/articles/psychedelics/cybin-receives-fda-breakthrough-therapy-designation-for-its-novel-psychedelic-molecule-cyb003-and-announces-positive-four-month-durability-data-in-major-depressive-disorder/